Over the past decade, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment
of cancer. In mesothelioma, a rare cancer with a dismal prognosis generally caused by …

Hepatocellular carcinoma (HCC) is one of the most common tumors in the world, and its
mortality is still on the rise. Limited treatments and low chemotherapy sensitivity of HCC …

The only registered systemic treatment for malignant pleural mesothelioma (MPM) is
platinum based chemotherapy combined with pemetrexed, with or without bevacizumab …

Immune checkpoint inhibitors (ICIs) have shown promising therapeutic effects in the
treatment of advanced solid cancers, but their overall response rate is still very low for …

Although mesothelioma is the consequence of a protracted immune response to asbestos
fibers and characterized by a clear immune infiltrate, novel immunotherapy approaches …

Background As a novel immune checkpoint molecular, T-cell immunoglobulin mucin 3 (TIM-
3) is emerging as a therapeutic target for cancer immunotherapy. However, the predictive …

Exosomes are membrane-bound, virus-sized vesicles present in circulating blood. Tumor
cells are avid producers of exosomes, which are thought to mimic molecular features of …

Malignant pleural mesothelioma (MPM) is an incurable cancer with a dismal prognosis and
few effective treatment options. Nonetheless, recent positive phase III trial results for immune …

Malignant pleural mesothelioma (MPM) is a rare and fatal disease of the pleural lining. Up to
80% of the MPM cases are linked to asbestos exposure. Even though its use has been …

Background Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and
CTLA-4 was suggested to yield clinical benefit over chemotherapy in malignant pleural …